Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch
of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution).
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z2 Ophthalmic Solution USP, 0.004% of Sandoz, Inc.
According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Z Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
 "Stock Market, BSE, Nifty, Capital")
 "Cyclone Dana, Cyclone, Dana")
 "Pollution, New Delhi Pollution")
 "Champions Trophy 2025")
 "Mohan Yadav, Mohan, MP CM")
